COTI-2 hydrochloride

COTI-2 (72 h treatment) hydrochloride inhibits the proliferation of all tested cancer cell lines, including HEC-1A, Ovcar-8, KLE, HL-60, A549 and H226, with IC₅₀ values ranging from near 0 nM to over 200 nM after 72 h of treatment^[1].
COTI-2 (96 h treatment) hydrochloride potently inhibits the proliferation of colorectal cancer cell lines SW620, COLO-205 and HCT-15, as well as non-small cell lung cancer (NSCLC) cell lines H292 and H1975, and exhibits superior efficacy to Cetuximab (HY-P9905) or Erlotinib (HY-50896) after 96 h of treatment^[1].
COTI-2 (4-7 days) hydrochloride inhibits the proliferation of U87-MG, SNB-19, SF-268 and SF-295 glioblastoma cell lines, with IC₅₀ values in the nanomolar range; after 4-7 days of treatment, its potency against U87-MG and SNB-19 cell lines is 10 to 500-fold that of Cisplatin (HY-17394) and BCNU (HY-13585)^[1].
COTI-2 (100-1000 nM; 48 h) hydrochloride induces apoptosis in small cell lung cancer SHP-77 cells. Specifically, treatment with IC₅₀ concentrations (100 nM, 250 nM) for 48 h results in early apoptosis in 40.13% to 46.68% of cells, while treatment with the IC₉₀ concentration (1000 nM) for 48 h induces early apoptosis as well as late apoptosis/necrosis in most cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.